Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Type 2 Diabetes: Clinical Updates and Perspectives
share announcement

Type 2 Diabetes: Clinical Updates and Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Endocrinology & Metabolism".

Deadline for manuscript submissions: closed (20 December 2022) | Viewed by 5160

Special Issue Editor

Prof. Dr. Min Xu

E-Mail Website
Guest Editor
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Interests: type 2 diabetes; cardiometabolic risk; genetic epidemiology; gene-environmental interaction

Special Issue Information

Dear Colleagues,

According to the newest IDF Atlas, 537 million (1 in 10) adults globally are now living with diabetes. Among them, over 90% have type 2 diabetes (T2DM), and this figure is projected to reach 783 million (12.2%) by 2045. T2DM, together with its related cardiometabolic risk profiles, impose a huge burden on cardiovascular diseases, mortality, and health care expenditure. Early identification and stratification for risk and cause of developing diabetes are crucial for better management and prevention of T2DM. The great technology development and integrative analysis advances in genomics, transcriptomics, epigenomics, metabolomics, and proteomics provide huge opportunities for deeper exploration of the etiology, prevention, and management strategies of T2DM. Research is needed to understand the etiology of T2DM, novel biomarkers, risk factors, or metabolic pathways that can predict T2DM, and to find successful methods or strategies to prevent T2DM.

This Special Issue will provide recent advances in clinical and translational research on T2DM. Therefore, researchers in the field of T2DM and related cardiometabolic diseases or consequences are encouraged to submit an original article or review to this Special Issue (case reports and short reviews will not be accepted).

Prof. Dr. Min Xu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • type 2 diabetes mellitus
  • cardiometabolic risk factors
  • biomarkers
  • omics
  • integrative analysis
  • prevention
  • management

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1011 KiB  
Article
Effect of Sarcopenia on Mortality in Type 2 Diabetes: A Long-Term Follow-Up Propensity Score-Matched Diabetes Cohort Study
by Jui-An Lin, Jin-De Hou and Szu-Yuan Wu
J. Clin. Med. 2022, 11(15), 4424; https://doi.org/10.3390/jcm11154424 - 29 Jul 2022
Cited by 5 | Viewed by 1494
Abstract
Purpose: The effect of sarcopenia on the survival of patients with type 2 diabetes remains unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the patients with diabetes with or without sarcopenia. Patients and Methods: We included patients with type [...] Read more.
Purpose: The effect of sarcopenia on the survival of patients with type 2 diabetes remains unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the patients with diabetes with or without sarcopenia. Patients and Methods: We included patients with type 2 diabetes and categorized them into two groups according to whether they had sarcopenia and compared their survival; patients in the groups were matched at a ratio of 1:2. Results: The matching process yielded a final cohort of 201,698 patients (132,805 and 68,893 in the sarcopenia and nonsarcopenia diabetes groups, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratios (aHRs; 95% confidence interval [CI]) of all-cause death for the sarcopenia diabetes group compared with the control group: 1.35 (1.33–1.38; p < 0.001). The aHRs (95% CIs) of all-cause death for those aged 41–50, 51–60, and >60 years (compared with those aged ≤40 years) were 1.53 (1.48–1.60), 2.61 (2.52–2.72), and 6.21 (5.99–6.45), respectively. The aHR (95% CI) of all-cause death for the male patients compared with the female patients was 1.56 (1.54–1.60). The aHRs (95% CIs) of all-cause death for those with adapted Diabetes Complications Severity Index (aDCSI) scores of 1, 2, 3, 4, and ≥5 (compared with an aDCSI score of 0) were 1.01 (1.00–1.14), 1.38 (1.35–1.42), 1.58 (1.54–1.63), and 2.23 (2.14–2.33), respectively. Conclusion: Patients with type 2 diabetes and sarcopenia had higher mortality than did those without sarcopenia. Full article
(This article belongs to the Special Issue Type 2 Diabetes: Clinical Updates and Perspectives)
►▼ Show Figures

Figure 1

10 pages, 880 KiB  
Article
Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
by Cristina Gavina, Daniel Seabra Carvalho, Daniel Martinho Dias, Filipa Bernardo, Hugo Martinho, João Couceiro, Carla Santos-Araújo, Ricardo Jorge Dinis-Oliveira and Tiago Taveira-Gomes
J. Clin. Med. 2022, 11(8), 2131; https://doi.org/10.3390/jcm11082131 - 11 Apr 2022
Cited by 5 | Viewed by 2981
Abstract
Introduction: Type 2 diabetes mellitus (T2D) increases the risk of heart failure (HF) and chronic kidney disease (CKD). Nonetheless, evidence of cardiovascular (CV) prognosis is relatively scarce in young T2D patients. Purpose: To estimate the risk of all-cause death, CV death, and non-fatal [...] Read more.
Introduction: Type 2 diabetes mellitus (T2D) increases the risk of heart failure (HF) and chronic kidney disease (CKD). Nonetheless, evidence of cardiovascular (CV) prognosis is relatively scarce in young T2D patients. Purpose: To estimate the risk of all-cause death, CV death, and non-fatal major CV events (MACEs) in T2D patients younger than 65 years old. Methods: We designed a retrospective cohort study using incident cases of either T2D, HF, or CKD in the population aged 40–65 years, from 1st January 2000 to 31st December 2019. Each individual was followed for up to one year. The primary analysis consisted of survival analysis with Cox proportional hazards to compare one-year risk of all-cause death, CV death, and MACEs between T2D without HF or CKD (T2D), T2D with HF (T2D-HF), and T2D with CKD (T2D-CKD) groups. Results: A total of 14,986 incident adult diabetic patients from the last two decades in our institution were included with an average age at cohort inclusion of 55–58 years old. Glycemic control was similar among groups. The adjusted hazard ratio (HR) of one-year all-cause death was 2.77 (95% CI: 2.26–3.40) for T2D-HF and 3.09 (2.77–3.45) for T2D-CKD compared with the baseline T2D risk. The highest event rate (T2D-CKD) was 0.15 per person-year. The adjusted HR of one-year CV death was 2.75 (95% CI: 2.19–3.46) for T2D-CKD and 2.59 (1.72–3.91) for T2D-HF. The non-fatal MACE risk was significantly increased in T2D-HF or T2D-CKD compared with T2D (2.82 (CI95%: 2.34–3.41) for T2D-CKD vs. 1.90 (CI95%: 1.66–2.17) for T2D-CKD) with a 32% event rate in non-fatal MACEs. Conclusions: Coexistence of HF or CKD is associated with increased premature mortality as well as non-fatal CV events in T2D patients under 65 years old. Full article
(This article belongs to the Special Issue Type 2 Diabetes: Clinical Updates and Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop